Mangoceuticals, Inc. (MGRX) stock
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$0.15−0.03 (-16.22%)
Close on Nov 13, 2026Market cap $3.34MP/E –Yield –
Mangoceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Mangoceuticals's operating margin for the twelve months ending Jun 30, 2026 was -3829.0%. For fiscal 2025 it was -3954.3%, against -1294.4% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3954.3% | −2659.9 |
| FY2024 | Dec 31, 2024 | -1294.4% | −34.1 |
| FY2023 | Dec 31, 2023 | -1260.3% | +21019.4 |
| FY2022 | Dec 31, 2022 | -22279.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1502.5% | +1631.5 |
| Q1 FY2026 | Mar 31, 2026 | -4606.8% | −420.0 |
| Q4 FY2025 | Dec 31, 2025 | -389.7% | +1204.3 |
| Q3 FY2025 | Sep 30, 2025 | -8953.5% | −7635.2 |
| Q2 FY2025 | Jun 30, 2025 | -3134.0% | −1804.9 |
| Q1 FY2025 | Mar 31, 2025 | -4186.8% | −3080.9 |
| Q4 FY2024 | Dec 31, 2024 | -1594.0% | −543.2 |
| Q3 FY2024 | Sep 30, 2024 | -1318.2% | −584.2 |
| Q2 FY2024 | Jun 30, 2024 | -1329.1% | +293.9 |
| Q1 FY2024 | Mar 31, 2024 | -1105.9% | +1434.9 |
| Q4 FY2023 | Dec 31, 2023 | -1050.9% | – |
| Q3 FY2023 | Sep 30, 2023 | -734.0% | – |
| Q2 FY2023 | Jun 30, 2023 | -1623.0% | – |
| Q1 FY2023 | Mar 31, 2023 | -2540.8% | – |
See a number that looks wrong?